Hydrocortisone for relative adrenal insufficiency in cirrhosis with refractory ascites or hepatorenal syndrome

Phase 2 trial of hydrocortisone in Cirrhosis, ascites, hepatorenal syndrome (HRS) and 1 more (2 cohorts), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoints: Incidence of relative adrenal insufficiency in cirrhotic patients with ascites without clinical sepsis and Effect of hydrocortisone on circulatory and renal function in refractory ascites/hepatorenal syndrome. Started Jul 2009; status: active.